Compare Abbott Laboratories (ABT) vs Nu Holdings Ltd (NU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Nu Holdings Ltd — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Nu Holdings Ltd trades at $13.36 (market cap $65.74B). The key difference: Abbott Laboratories is far larger — about 2.5× Nu Holdings Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| ABT | NU | |
|---|---|---|
Market Cap | $166.94B | $65.74B |
Sector | Health | Financials |
52-Week High | $136.62 | $18.76 |
52-Week Low | $82.57 | $11.60 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NU stock trades at $13.61, showing no change in the last 24 hours. The technical outlook is bullish based on moving averages, with key support at $13 and resistance at $14. Fundamentally, the company demonstrates robust growth, with revenue increasing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings show mixed results, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026 against expectations.
The investment outlook is positive, supported by strong analyst consensus with a $14.98 price target and 55% buy ratings. Key opportunities include expansion in Latin America and a high return on equity of 30.04%. Risks involve recent earnings misses, competitive pressures, and macroeconomic volatility in emerging markets. The stock presents a growth opportunity but requires monitoring of execution and regional economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
